Get started
Work

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer

Year: 2026
Type: article
Abstract: Prostate cancers with high proliferation rates have shorter survival times but when spread has occurred (metastatic), there is increased sensitivity to hormone therapy with abiraterone. .
DOI: 10.1172/jci203201
Authors: Larissa Mendes, Peter F. Dutey-Magni, Emily Grist, Ashwin Sachdeva, Sara Santos Vidal, Sharanpreet Lall, Marina A. Parry, Claire L. Amos, Nafisah Atako, Anna Wingate, Daniel Wetterskog, Matthew R. Sydes, Chris C. Parker, Noel Clarke, Christopher J. Sweeney, Mahesh K. Parmar, Louise C. Brown, Nicholas D. James, Daniel M. Berney, Gerhardt Attard
Institutions: University College London, University of Manchester, Institute of Cancer Research, Royal Marsden Hospital, University of South Australia, Queen Mary University of London
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $5,200
Funders: Prostate Cancer Foundation, Pfizer, Sanofi, Clovis Oncology, Cancer Research UK, National Institute for Health and Care Research, Prostate Cancer UK, Astellas Pharma, John Black Charitable Foundation, National Institutes of Health, Medical Research Council, National Cancer Institute
Awards: G213718030, G2221899572, G2463025383, G2978326887, G3114799256, G3747035981, G3882831376, G4258354855, G5064308886, G6352384130, G6731147368, G6777750634, G6908885602, G7348760956, G8363072258, Evaluating new healthcare technologies in cancer, Cancer Detection & Diagnosis Research-2022-Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
OpenAlex ID: W7147075771
FWCI:
Cites:
Cited by:
Related to: